Epstein-barr Virus Infections
📧 Sign up to get email alerts when something new happens for Epstein-barr Virus Infections.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-08-08Clinical Trial Update: EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection [Phase 2]
Phase 2 trial of EBV-specific cytotoxic T-lymphocytes for refractory Epstein-Barr virus infection is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-05-14Clinical Trial Update: A Study of the Safety and Efficacy of EBV Specific T-cell Lines [Phase 1, Phase 2]
A completed Phase 1/2 study evaluated the safety and efficacy of Epstein-Barr virus–specific T-cell lines in patients with Epstein-Barr viru…
-
CLINICAL_TRIALS trial_result · 2024-05-07Clinical Trial Update: Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant [Phase 2, Phase 3]
Clinical trial update reporting completed results for Posoleucel (ALVR105) studied to prevent multiple viral infections after allogeneic hem…
-
CLINICAL_TRIALS trial_result · 2022-08-02Clinical Trial Update: Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial [Phase 1, Phase 2]
Pilot trial investigating ex-vivo delivery of rituximab to prevent PTLD in EBV mismatch lung transplant recipients; Phase 1/2 study with unk…
-
CLINICAL_TRIALS trial_result · 2022-03-16Clinical Trial Update: ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation [Phase 2]
Phase 2 trial comparing valganciclovir to valacyclovir for viral prophylaxis in kidney transplantation; results posted after completion.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-07-28Clinical Trial Update: Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy [Phase 2]
Phase 2 clinical trial assessing a recombinant EBV vaccine for nasopharyngeal cancer patients with residual EBV DNA after standard therapy.
-
CLINICAL_TRIALS trial_result · 2015-01-29Clinical Trial Update: Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts [Phase 1]
A Phase 1 trial evaluated infusion of Epstein-Barr virus–specific killer T lymphocytes in patients who have had donor marrow transplants. Th…